ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

STRO vs IVVD // ALTMAN Z-SCORE & DEBT/EQUITY

Sutro Biopharma Inc. (NASDAQ) VS. Invivyd Inc. (NASDAQ) • 15-METRIC TALLY: STRO 1 — IVVD 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (STRO VS. IVVD) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC STRO IVVD SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 65.20% 110.50% -45.30 IVVD /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 STRO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 25.2 36.2 -11.00 IVVD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $150.9M $171.5M -$20.6M IVVD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR STRO REV IVVD REV STRO GROSS % IVVD GROSS % STRO FCF IVVD FCF
FY 2025 $102.5M $53.4M — — -$177.2M -$58.3M
FY 2024 $62.0M $25.4M — — -$191.5M -$170.6M
FY 2023 $153.7M $595.7M — — -$111.6M -$173.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
STRO // BETA —
IVVD // BETA —